Petah Tiqva, Israel
Petah Tiqva, Israel

Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company headquartered in Petah Tikva, Israel Wikipedia.


Time filter

Source Type

Patent
Teva Pharmaceutical Industries | Date: 2015-03-13

The subject invention provides an oral patch comprising: a) a liner; and b) a film composition thereon, the film composition comprising (i) laquinimod in an amount of about 0.1%-20% by weight of the film composition, and (ii) one or more film forming agents in a total amount of about 40%-90% by weight of the film composition. The subject invention also provides a method for delivering laquinimod across the oral mucosa of a subject, or for treating a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to the human subject an oral patch as described herein. The subject invention also provides an oral patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.


The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.


Patent
Teva Pharmaceutical Industries | Date: 2016-10-11

The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.


Patent
Teva Pharmaceutical Industries | Date: 2016-07-28

A stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, a therapeutically effective amount of glatiramer acetate related drug substance, and an amount of an amino acid. A process for making a stable pharmaceutical in liquid form, a sealed package comprising a stable pharmaceutical composition as described herein, and a use of a stable pharmaceutical composition as described herein. A method for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome, alleviating a symptom of multiple sclerosis in a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome, and/or providing neuroprotection to a subject in need thereof, comprising administering to the subject a composition as described herein.


Patent
Teva Pharmaceutical Industries | Date: 2016-06-10

This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.


The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.


Patent
Teva Pharmaceutical Industries | Date: 2016-06-07

This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.


Patent
Teva Pharmaceutical Industries | Date: 2016-10-06

This application provides for a method of treating a subject suffering from Crohns disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohns disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohns disease.


The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.


Patent
Teva Pharmaceutical Industries | Date: 2016-02-22

This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon- for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon- in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon- in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

Loading Teva Pharmaceutical Industries collaborators
Loading Teva Pharmaceutical Industries collaborators